{
  "company_name": "Krystal Biotech",
  "overview": "Krystal Biotech is focused on developing and commercializing gene therapies for dermatological diseases. The company's proprietary platform is based on engineered herpes simplex virus (HSV) vectors. Krystal Biotech halted a phase 2 study of its lead asset, KB707, for the treatment of skin cancer, indicating a strategic pivot or potential execution challenges.",
  "location": "Pittsburgh, PA, USA",
  "website": "https://www.krystalbio.com",
  "therapeutic_areas": [
    "oncology",
    "dermatology"
  ],
  "clinical_trials": {
    "phase_2_failed": [
      {
        "nct_id": null,
        "title": "A Phase 2 Study of KB707 in Patients With Skin Cancer",
        "condition_or_disease": "Skin Cancer",
        "intervention_name": "KB707",
        "phase": null,
        "status": "Terminated",
        "sponsor": "Krystal Biotech",
        "why_stopped": "Halted enrollment, specific reasons not disclosed",
        "completion_date": null
      }
    ],
    "phase_3_failed": [],
    "dormant_assets": []
  },
  "drug_assets": [
    {
      "name": "KB707",
      "modality": "gene therapy",
      "indication": "Skin Cancer",
      "development_stage": "phase 2",
      "target": null
    }
  ],
  "decision_makers": [
    {
      "name": "Krish Krishnan",
      "role": "Chairman/CEO at Krystal Biotech, Inc. ...",
      "linkedin_url": "https://www.linkedin.com/in/krish-krishnan-3a0b43115",
      "email": null,
      "source": "serpapi"
    },
    {
      "name": "Suma Krishnan",
      "role": "Founder & President at Krystal Biotech, Inc.",
      "linkedin_url": "https://www.linkedin.com/in/suma-krishnan-781130116",
      "email": null,
      "source": "serpapi"
    },
    {
      "name": "David C.",
      "role": "Krystal Biotech, Inc.",
      "linkedin_url": "https://www.linkedin.com/in/davidchienmd",
      "email": null,
      "source": "serpapi"
    },
    {
      "name": "Andy Orth",
      "role": "Krystal Biotech, Inc.",
      "linkedin_url": "https://www.linkedin.com/in/andy-orth-87822a6",
      "email": null,
      "source": "serpapi"
    },
    {
      "name": "David Sweet MD, PhD",
      "role": "Director of Clinical Development at ...",
      "linkedin_url": "https://www.linkedin.com/in/dsweetmdphd",
      "email": null,
      "source": "serpapi"
    }
  ],
  "investors": [],
  "fit_score_for_convexia": 75,
  "reason_for_fit_score": "Krystal Biotech's termination of the phase 2 study for KB707 due to undisclosed reasons, combined with their focus on gene therapy for dermatological diseases, presents a potential opportunity for Convexia to explore rescue strategies. The company's strong scientific foundation and proprietary HSV vector platform suggest a high potential for addressing execution challenges.",
  "data_sources_used": [
    "https://www.oncologynewscentral.com/oncology/halted-trials-patient-deaths-and-more-recent-new-on-oncology-research-concerns"
  ],
  "last_updated": "2025-11-17 22:50:03.983811"
}